<p>欢迎来到 <em>Pharmaceutical Executive Daily</em>，这是您快速了解制药和生命科学行业最新动态的简报。</p>
<p>在今天的 <em>Pharmaceutical Executive Daily</em> 中，FDA 批准 BeOne Medicines 的 Beqalzi 加速上市，成为首个也是唯一一个用于复发或难治性边缘细胞淋巴瘤的 BCL2 抑制剂，同时也批准了 Taiho Oncology 的 Inqovi 与 venetoclax 联合用于新诊断的急性髓性白血病，Pharmaceutical Executive 报道了 Doceree Makers Summit，Dean Erhardt 认为，AI 驱动的工作流自动化为修复先前授权系统的长期失败提供了切实可行的路径。</p>
<p>FDA 针对难治性血癌推出了两种新疗法。BeOne Medicines 获得了 Beqalzi（sonrotoclax）的批准，这是一种新一代 BCL2 抑制剂，适用于接受过至少两种系统治疗（包括 BTK 抑制剂）的复发或难治性边缘细胞淋巴瘤成人患者，使其成为首个专门针对 MCL 批准的 BCL2 抑制剂，并在 BTK 抑制剂后疗法中提供了一种药理上不同的选择，历史上该领域的治疗效果较差。该批准得到了 BGB-11417-201 试验的 1/2 期数据的支持，显示在接受过抗 CD20 治疗和 BTK 抑制剂的患者中，总体反应率为 52%，中位反应持续时间为 15.8 个月。另一方面，Taiho Oncology 获得了 Inqovi 的批准——其口服地西他滨和 cedazuridine 组合——与 venetoclax 联合用于新诊断的急性髓性白血病的老年或不适合患者，该方案实现了 41.6% 的完全缓解率，中位反应时间约为两个月，提供了一种全口服的替代方案，取代现有的基于输注的低甲基化剂和 venetoclax 方案。</p>
<p>Doceree Makers Summit 会议上，来自 Sanofi、Bristol Myers Squibb 和 Eli Lilly 等公司的代表聚集在一起，讨论与会者所描述的制药商业战略中的一个决定性运营挑战：碎片化、脱节的营销技术堆栈的激增，使得在规模上实现统一的客户参与和测量变得困难。与会者支持围绕集成平台而非传统点解决方案构建的新制药营销运营模型，反映出行业普遍共识，即当前的架构通过多年的软件收购积累而成，造成数据孤岛，减缓了活动执行，并削弱了跟踪促销投资在各渠道和客户接触点的全面影响的能力。</p>
<p>最后，Dean Erhardt 提出，当前的系统结构对患者造成了损害，导致延误、放弃和临床伤害，而在授权工作流中有针对性地部署 AI 提供了一条切实可行的、近期的改善路径。Erhardt 认为，问题不仅仅是行政负担，而是一个从未为当今特殊药物领域的数量和复杂性设计的工作流架构，能够自动化文档检索、预测批准可能性并在提交到支付方之前标记不完整提交的 AI 工具，可以减少周期时间，提高批准率，而无需进行先前授权改革立法迄今未能实现的系统性监管改革。</p>
<p>感谢您收听 <em>Pharmaceutical Executive Daily</em>。欲获取更多更新和深入分析，请访问 PharmExec.com。</p>

百济神州

IBBQ

美国制药 ETF - iShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

<p>FDA 已对 BeOne Medicines 的 Beqalzi 和 Taiho Oncology 的 Inqovi 给予加速批准，前者是首个用于复发性披衣淋巴瘤的 BCL2 抑制剂，后者则用于新诊断的急性髓性白血病。Doceree Makers Summit 强调了制药行业对综合营销技术的需求，而 Dean Erhardt 提出了利用人工智能实现工作流程自动化，以改善事前授权系统。Beqalzi 在试验中显示出 52% 的应答率，而 Inqovi 则达到了 41.6% 的完全缓解率，为棘手的血液癌症提供了新的治疗选择</p>

<p>Welcome to <em>Pharmaceutical Executive Daily</em>, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.</p>
<div class="lb-trans"><p>欢迎来到 <em>Pharmaceutical Executive Daily</em>，这是您快速了解制药和生命科学行业最新动态的简报。</p>
</div><p>In today's <em>Pharmaceutical Executive Daily</em>, the FDA grants accelerated approval to BeOne Medicines' Beqalzi as the first and only BCL2 inhibitor for relapsed or refractory mantle cell lymphoma, while also approving Taiho Oncology's Inqovi in combination with venetoclax for newly diagnosed acute myeloid leukemia, Pharmaceutical Executive reports on the Doceree Makers Summit, and Dean Erhardt argues that AI-enabled workflow automation offers a practical path to fixing the prior authorization system's chronic failures.</p>
<div class="lb-trans"><p>在今天的 <em>Pharmaceutical Executive Daily</em> 中，FDA 批准 BeOne Medicines 的 Beqalzi 加速上市，成为首个也是唯一一个用于复发或难治性边缘细胞淋巴瘤的 BCL2 抑制剂，同时也批准了 Taiho Oncology 的 Inqovi 与 venetoclax 联合用于新诊断的急性髓性白血病，Pharmaceutical Executive 报道了 Doceree Makers Summit，Dean Erhardt 认为，AI 驱动的工作流自动化为修复先前授权系统的长期失败提供了切实可行的路径。</p>
</div><p>The FDA has two new treatments for difficult-to-treat blood cancers. BeOne Medicines received approval for Beqalzi, sonrotoclax, a next-generation BCL2 inhibitor — for adult patients with relapsed or refractory mantle cell lymphoma who have received at least two prior lines of systemic therapy including a BTK inhibitor, making it the first and only BCL2 inhibitor approved specifically for MCL and adding a pharmacologically distinct option in a post-BTK inhibitor setting where outcomes have historically been poor. The approval was supported by Phase 1/2 data from the BGB-11417-201 trial showing a 52 percent overall response rate and a median duration of response of 15.8 months in patients previously treated with anti-CD20 therapy and a BTK inhibitor. Separately, Taiho Oncology received approval for Inqovi — its oral decitabine and cedazuridine combination — in combination with venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia, where the regimen achieved a 41.6 percent complete remission rate with a median time to response of approximately two months, offering an all-oral alternative to existing infusion-based hypomethylating agent and venetoclax regimens.</p>
<div class="lb-trans"><p>FDA 针对难治性血癌推出了两种新疗法。BeOne Medicines 获得了 Beqalzi（sonrotoclax）的批准，这是一种新一代 BCL2 抑制剂，适用于接受过至少两种系统治疗（包括 BTK 抑制剂）的复发或难治性边缘细胞淋巴瘤成人患者，使其成为首个专门针对 MCL 批准的 BCL2 抑制剂，并在 BTK 抑制剂后疗法中提供了一种药理上不同的选择，历史上该领域的治疗效果较差。该批准得到了 BGB-11417-201 试验的 1/2 期数据的支持，显示在接受过抗 CD20 治疗和 BTK 抑制剂的患者中，总体反应率为 52%，中位反应持续时间为 15.8 个月。另一方面，Taiho Oncology 获得了 Inqovi 的批准——其口服地西他滨和 cedazuridine 组合——与 venetoclax 联合用于新诊断的急性髓性白血病的老年或不适合患者，该方案实现了 41.6% 的完全缓解率，中位反应时间约为两个月，提供了一种全口服的替代方案，取代现有的基于输注的低甲基化剂和 venetoclax 方案。</p>
</div><p>The Doceree Makers Summit, where approximately from companies including Sanofi, Bristol Myers Squibb, and Eli Lilly convened to address what participants described as a defining operational challenge in pharmaceutical commercial strategy: the proliferation of fragmented, disconnected marketing technology stacks that make unified customer engagement and measurement difficult at scale. Attendees backed a new pharma marketing operating model built around integrated platforms rather than legacy point solutions, reflecting a broader industry consensus that the current architecture, accumulated through years of bolt-on software acquisitions, creates data silos, slows campaign execution, and undermines the ability to track the full impact of promotional investment across channels and customer touchpoints.</p>
<div class="lb-trans"><p>Doceree Makers Summit 会议上，来自 Sanofi、Bristol Myers Squibb 和 Eli Lilly 等公司的代表聚集在一起，讨论与会者所描述的制药商业战略中的一个决定性运营挑战：碎片化、脱节的营销技术堆栈的激增，使得在规模上实现统一的客户参与和测量变得困难。与会者支持围绕集成平台而非传统点解决方案构建的新制药营销运营模型，反映出行业普遍共识，即当前的架构通过多年的软件收购积累而成，造成数据孤岛，减缓了活动执行，并削弱了跟踪促销投资在各渠道和客户接触点的全面影响的能力。</p>
</div><p>Finally, Dean Erhardt makes the case that is structurally broken for patients, creating delays, abandonment, and clinical harm, and that targeted deployment of AI within authorization workflows offers a practical and near-term path to meaningful improvement. Erhardt argues that the problem is not simply administrative burden but a workflow architecture that was never designed for the volume and complexity of today's specialty drug landscape, and that AI tools capable of automating documentation retrieval, predicting approval likelihood, and flagging incomplete submissions before they reach payers can reduce cycle times and improve approval rates without requiring the systemic regulatory overhaul that prior authorization reform legislation has so far failed to deliver.</p>
<div class="lb-trans"><p>最后，Dean Erhardt 提出，当前的系统结构对患者造成了损害，导致延误、放弃和临床伤害，而在授权工作流中有针对性地部署 AI 提供了一条切实可行的、近期的改善路径。Erhardt 认为，问题不仅仅是行政负担，而是一个从未为当今特殊药物领域的数量和复杂性设计的工作流架构，能够自动化文档检索、预测批准可能性并在提交到支付方之前标记不完整提交的 AI 工具，可以减少周期时间，提高批准率，而无需进行先前授权改革立法迄今未能实现的系统性监管改革。</p>
</div><p>Thanks for listening to <em>Pharmaceutical Executive Daily</em>. For more updates and in-depth analysis, visit PharmExec.com.</p>
<div class="lb-trans"><p>感谢您收听 <em>Pharmaceutical Executive Daily</em>。欲获取更多更新和深入分析，请访问 PharmExec.com。</p>
</div>

制药执行日报：FDA 批准了 Beqalzi 和 Inqovi